Auris Medical Holding is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company focused on the development of products that address medical needs in neurotology and mental health supportive care. Co. is focusing on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. In addition, Co. has two programs under development: Keyzilen®, which is being developed for the treatment of acute inner ear tinnitus; and Sonsuvi®, which is being developed for the treatment of acute inner ear hearing loss. We show 6 historical shares outstanding datapoints in our EARS shares outstanding history coverage, used to compute EARS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing EARS market cap history over the course of time is important for investors
interested in comparing EARS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of EARS versus a peer is one thing; comparing
EARS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like EARS can fluctuate over the course of history.
With this page we aim to empower investors researching EARS by allowing them to research the EARS market cap history. |
Free EARS Email Alerts:
Video: The Importance of Market Cap
